Eiger BioPharmaceuticals, Inc. EIGRQ
8.50
0.00
0.00%
as of 1 Oct
- Market cap
- $2.6M
- P/E
- 0.0×
Follow EIGRQ
Growth Flags
show if company had growth for consecutive years
| Older periods | Mar '23 | Jun '23 | Sep '23 | Dec '23 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.65 | 2.01 | 0.90 | 0.66 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.65) | (1.41) | (0.91) | (0.75) | |
P/B ratio |
1.12 | 2.04 | 0.00 | 0.00 | |
Price to Tangible BV |
1.12 | 2.04 | 0.00 | 0.00 | |
EV/Sales |
0.32 | 1.18 | 1.01 | 4.24 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.05) | (0.20) | (0.18) | (0.90) | |
EV/FCF |
(0.05) | (0.20) | (0.18) | (0.90) | |
Quick Ratio |
3.30 | 3.43 | 2.47 | 0.51 | |
Current Ratio |
4.04 | 4.22 | 3.31 | 0.71 | |
Net Debt/EBITDA |
1.54 | 0.64 | (0.09) | (1.24) | |
Debt/Assets |
40.74% | 56.21% | 73.56% | 105.91% | |
Debt/Equity |
1.15 | 2.66 | (25.52) | (2.84) | |
Asset Turnover |
0.12 | 0.13 | 0.15 | 0.20 | |
Operating CF/Net income |
1.05 | 1.06 | 0.81 | 1.04 | |
Capex/Depreciation |
0.72 | 0.05 | 0.00 | 0.11 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
406.70% | 417.85% | 453.97% | 305.39% | |
Selling, General and Administrative Expense of Revenue |
231.06% | 119.17% | 169.96% | 123.64% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
61.73% | 16.05% | 32.35% | 17.96% | |
Graham Net Nets |
0.83 | 0.43 | (0.20) | (1.48) | |
Graham Number |
0.00 | 0.00 | 38.03 | 106.11 | |
Earnings Yield |
(247.74%) | (309.97%) | (659.52%) | (723.58%) | |
Free Cash Flow Yield |
(224.75%) | (286.35%) | (627.68%) | (715.72%) | |
Revenue per Share |
2.80 | 3.15 | 2.17 | 2.58 | |
Operating CF per Share |
(16.33) | (14.94) | (9.86) | (9.45) | |
Capex per Share |
(0.15) | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(16.48) | (14.95) | (9.86) | (9.45) | |
Cash per Share |
51.20 | 36.34 | 26.71 | 17.24 | |
Shareholders Equity per Share |
23.97 | 10.37 | (1.09) | (9.80) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
23.97 | 10.37 | (1.09) | (9.80) | |
Free Cash Flow |
(24.22) | (22.05) | (14.55) | (13.95) | |
Working Capital |
72.91 | 53.77 | 38.10 | (15.44) | |
Capital Expenditures |
(0.22) | (0.02) | 0.00 | 0.00 | |
Net Current Asset Value |
32.92 | 13.42 | (2.63) | (15.44) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(553.28%) | (445.72%) | (561.86%) | (353.77%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.09 | 2.38 | 1.89 | 1.72 | |
Average Payables |
10.54 | 7.45 | 7.68 | 5.55 | |
Average Inventory |
3.62 | 1.99 | 1.96 | 2.20 | |
Average Assets |
126.28 | 118.02 | 99.70 | 79.48 | |
Average Common Equity |
66.25 | 59.11 | 38.35 | 20.43 |
Columns are period end dates